Corvus Pharmaceuticals, Inc. Operating Expenses
Corvus Pharmaceuticals, Inc. (CRVS) reported Operating Expenses of $19.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $19.30M, a 88.08% increase year-over-year.
- Corvus Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $14.88M, a 49.94% increase year-over-year.
- Corvus Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $12.22M, a 50.73% increase year-over-year.
- Corvus Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $10.57M, a 45.72% increase year-over-year.
- Corvus Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $42.97M, a 55.99% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $27.55M, a 17.69% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $23.41M, a 28.12% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $32.56M, a 15.70% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.30M 10-Q · filed 2026-08-06 | $34.17M 10-Q · filed 2026-08-06 | $46.39M derived: sum of 3 quarters · filed 2026-08-06 | $56.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.88M 10-Q · filed 2026-05-07 | $27.09M derived: sum of 2 quarters · filed 2026-05-07 | $37.67M derived: sum of 3 quarters · filed 2026-05-07 | $47.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $12.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $22.79M derived: sum of 2 quarters · filed 2026-03-12 | $33.05M derived: sum of 3 quarters · filed 2026-08-06 | $42.97M 10-K · filed 2026-03-12 |
| 2025-09-30 | $10.57M 10-Q · filed 2025-11-04 | $20.83M derived: sum of 2 quarters · filed 2026-08-06 | $30.75M 10-Q · filed 2025-11-04 | $38.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.26M 10-Q · filed 2026-08-06 | $20.18M 10-Q · filed 2026-08-06 | $28.29M derived: sum of 3 quarters · filed 2026-08-06 | $35.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.92M 10-Q · filed 2026-05-07 | $18.03M derived: sum of 2 quarters · filed 2026-05-07 | $25.28M derived: sum of 3 quarters · filed 2026-05-07 | $31.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $15.36M derived: sum of 2 quarters · filed 2026-03-12 | $21.30M derived: sum of 3 quarters · filed 2026-03-12 | $27.55M 10-K · filed 2026-03-12 |
| 2024-09-30 | $7.25M 10-Q · filed 2025-11-04 | $13.19M derived: sum of 2 quarters · filed 2025-11-04 | $19.44M 10-Q · filed 2025-11-04 | $25.09M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $5.93M 10-Q · filed 2025-08-07 | $12.19M 10-Q · filed 2025-08-07 | $17.84M derived: sum of 3 quarters · filed 2026-03-12 | $23.40M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $6.25M 10-Q · filed 2025-05-08 | $11.90M derived: sum of 2 quarters · filed 2026-03-12 | $17.46M derived: sum of 3 quarters · filed 2026-03-12 | $23.09M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $11.21M derived: sum of 2 quarters · filed 2026-03-12 | $16.83M derived: sum of 3 quarters · filed 2026-03-12 | $23.41M 10-K · filed 2026-03-12 |
| 2023-09-30 | $5.56M 10-Q · filed 2024-11-12 | $11.18M derived: sum of 2 quarters · filed 2024-11-12 | $17.76M 10-Q · filed 2024-11-12 | $23.42M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-06-30 | $5.62M 10-Q · filed 2024-08-06 | $12.20M 10-Q · filed 2024-08-06 | $17.86M derived: sum of 3 quarters · filed 2025-03-25 | $30.34M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-03-31 | $6.57M 10-Q · filed 2024-05-07 | $12.24M derived: sum of 2 quarters · filed 2025-03-25 | $24.71M derived: sum of 3 quarters · filed 2025-03-25 | $31.73M derived: sum of 4 quarters · filed 2025-03-25 |
| 2022-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $18.14M derived: sum of 2 quarters · filed 2025-03-25 | $25.15M derived: sum of 3 quarters · filed 2025-03-25 | $32.56M 10-K · filed 2025-03-25 |
| 2022-09-30 | $12.47M 10-Q · filed 2023-11-07 | $19.49M derived: sum of 2 quarters · filed 2023-11-07 | $26.90M 10-Q · filed 2023-11-07 | $33.71M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $7.01M 10-Q · filed 2023-08-08 | $14.43M 10-Q · filed 2023-08-08 | $21.24M derived: sum of 3 quarters · filed 2023-08-08 | $30.28M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $7.41M 10-Q · filed 2023-05-08 | $14.22M derived: sum of 2 quarters · filed 2023-05-08 | $23.27M derived: sum of 3 quarters · filed 2023-05-08 | $34.56M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $6.81M 10-K · filed 2022-03-10 | $15.86M derived: sum of 2 quarters · filed 2022-11-03 | $27.15M derived: sum of 3 quarters · filed 2022-11-03 | $38.63M 10-K · filed 2024-03-19 |
| 2021-09-30 | $9.05M 10-Q · filed 2022-11-03 | $20.34M derived: sum of 2 quarters · filed 2022-11-03 | $31.82M 10-Q · filed 2022-11-03 | $41.70M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $11.29M 10-Q · filed 2022-08-08 | $22.77M 10-Q · filed 2022-08-08 | $32.65M derived: sum of 3 quarters · filed 2022-08-08 | $42.50M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $11.48M 10-Q · filed 2022-05-05 | $21.36M derived: sum of 2 quarters · filed 2022-05-05 | $31.21M derived: sum of 3 quarters · filed 2022-05-05 | $41.97M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $9.88M 10-K · filed 2022-03-10 | $19.72M derived: sum of 2 quarters · filed 2022-03-10 | $30.49M derived: sum of 3 quarters · filed 2022-03-10 | $43.76M 10-K · filed 2023-03-28 |
| 2020-09-30 | $9.85M 10-K · filed 2022-03-10 | $20.61M derived: sum of 2 quarters · filed 2022-03-10 | $33.88M 10-Q · filed 2021-11-01 | $45.32M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $10.77M 10-K · filed 2022-03-10 | $24.04M 10-Q · filed 2021-08-02 | $35.48M derived: sum of 3 quarters · filed 2022-03-10 | $46.99M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $13.27M 10-K · filed 2022-03-10 | $24.71M derived: sum of 2 quarters · filed 2022-03-10 | $36.22M derived: sum of 3 quarters · filed 2022-03-10 | $49.82M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $11.44M 10-K · filed 2021-03-25 | $22.95M derived: sum of 2 quarters · filed 2021-03-25 | $36.55M derived: sum of 3 quarters · filed 2021-03-25 | $48.85M 10-K · filed 2022-03-10 |
| 2019-09-30 | $11.51M 10-K · filed 2021-03-25 | $25.11M derived: sum of 2 quarters · filed 2021-03-25 | $37.41M 10-Q · filed 2020-10-29 | $48.59M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $13.60M 10-K · filed 2021-03-25 | $25.90M 10-Q · filed 2020-07-30 | $37.07M derived: sum of 3 quarters · filed 2021-03-25 | $48.22M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $12.30M 10-K · filed 2021-03-25 | $23.48M derived: sum of 2 quarters · filed 2021-03-25 | $34.63M derived: sum of 3 quarters · filed 2021-03-25 | $46.88M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $11.17M 10-K · filed 2020-03-09 | $22.32M derived: sum of 2 quarters · filed 2020-03-09 | $34.58M derived: sum of 3 quarters · filed 2020-03-09 | $49.22M 10-K · filed 2021-03-25 |
| 2018-09-30 | $11.15M 10-K · filed 2020-03-09 | $23.41M derived: sum of 2 quarters · filed 2020-03-09 | $38.05M 10-Q · filed 2019-10-29 | $50.24M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-06-30 | $12.26M 10-K · filed 2020-03-09 | $26.90M 10-Q · filed 2019-08-01 | $39.09M derived: sum of 3 quarters · filed 2020-03-09 | $52.03M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-03-31 | $14.64M 10-K · filed 2020-03-09 | $26.83M derived: sum of 2 quarters · filed 2020-03-09 | $39.78M derived: sum of 3 quarters · filed 2020-03-09 | $54.95M derived: sum of 4 quarters · filed 2020-03-09 |
| 2017-12-31 | $12.19M 10-K · filed 2019-03-07 | $25.13M derived: sum of 2 quarters · filed 2019-03-07 | $40.31M derived: sum of 3 quarters · filed 2019-03-07 | $56.52M 10-K · filed 2020-03-09 |
| 2017-09-30 | $12.94M 10-K · filed 2019-03-07 | $28.12M derived: sum of 2 quarters · filed 2019-03-07 | $44.34M 10-Q · filed 2018-11-01 | $55.58M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $15.17M 10-K · filed 2019-03-07 | $31.39M 10-Q · filed 2018-08-02 | $42.64M derived: sum of 3 quarters · filed 2019-03-07 | $53.12M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $16.22M 10-K · filed 2019-03-07 | $27.47M derived: sum of 2 quarters · filed 2019-03-07 | $37.94M derived: sum of 3 quarters · filed 2019-03-07 | $46.77M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $11.25M 10-K · filed 2018-03-01 | $21.73M derived: sum of 2 quarters · filed 2018-03-01 | $30.55M derived: sum of 3 quarters · filed 2018-03-01 | $36.98M 10-K · filed 2019-03-07 |
| 2016-09-30 | $10.48M 10-K · filed 2018-03-01 | $19.30M derived: sum of 2 quarters · filed 2018-03-01 | $25.73M derived: sum of 3 quarters · filed 2018-03-01 | |
| 2016-06-30 | $8.82M 10-K · filed 2018-03-01 | $15.25M 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | $6.43M 10-K · filed 2018-03-01 | |||
| 2015-12-31 | $13.77M 10-K · filed 2018-03-01 | |||
| 2015-06-30 | $2.33M 10-Q · filed 2016-08-04 | $4.55M 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $2.21M 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |